MGMichael Gilbert

Michael Gilbert

*This is an algorithmically generated author record based on publicly available information.

Michael Gilbert has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages

    by Michael K Gilbert, Ashlynn R Daughton, Howard D Chilcoat, Celine M Laffont, Stephanie Strafford, Angela M DeVeaugh-Geiss

    Background: Discontinuation of buprenorphine as a medication for opioid use disorder (MOUD) necessitates careful tapering to reduce opioid withdrawal and relapse. With a half-life of 43-60 days, buprenorphine extended-release formulation (BUP-XR) may provide gradual taper, facilitating successful treatment discontinuation. Objective: This study sought to understand experiences with stopping BUP-XR as described on social media. Methods: Reddit records (March 2018 to August 2022) were evaluated for the presence of referents to BUP-XR using parallel criteria based on predefined keywords and subreddit context. The keyword-based search identified records mentioning “Sublocade” (or similar search strings) regardless of subreddit. The subreddit context-based criteria identified records that were created within the r/Sublocade subreddit. Records that included reference to BUP-XR were further evaluated for mentions of treatment cessation using predefined keywords. A 50% randomized sample was then selected for qualitative analysis by a single experienced subject matter expert. Records were manually coded to validate references to BUP-XR and MOUD cessation and were evaluated for additional predefined constructs related to opioid craving and withdrawal, BUP-XR and other MOUD treatment details, and other nonmedical opioid use. Emergent constructs related to cessation-related knowledge, attitudes, behaviors, and experiences were also identified as part of the data coding and annotation process. Results: Of 6082 total, 3041 records were coded and analyzed; most (n=2692, 97.4%) referenced BUP-XR, of which, 43.8% (n=1179) referenced cessation of BUP-XR as MOUD. Many individuals shared information about prior use of MOUD, primarily transmucosal buprenorphine (185 records/63 authors), including the use of BUP-XR to taper off buprenorphine. Individuals provided details of their BUP-XR treatment experiences before and following cessation. Only 102 (8.7%) records mentioned opioid withdrawal; 1 record mentioned craving. Withdrawal experiences with BUP-XR were generally described as less intense than other drugs, although at least mild withdrawal was seen as an inevitable part of cessation. Thematic analysis revealed discussions of polypharmacy with transmucosal buprenorphine and the importance of personalized treatment and patient agency. Conclusions: There was nuanced discussion of treatment cessation using BUP-XR on Reddit, with individuals describing detailed courses of treatment and treatment experiences. Few records mentioned opioid withdrawal, and when discussed, withdrawal experiences during cessation of BUP-XR were generally described as less intense than withdrawal experiences with other drugs. These results suggest that social media, such as Reddit, can be leveraged to explore perspectives on treatment and recovery among individuals with opioid use disorder. Overall, this study provides insights into real-world patient experiences with cessation of BUP-XR and is consistent with prior case series; however, more research is needed to understand the course of opioid use disorder following cessation of BUP-XR as well as other MOUD.


  • Open Access

    Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages (Preprint)

    by Michael K Gilbert, Ashlynn R Daughton, Howard D Chilcoat, Celine M Laffont, Stephanie Strafford, Angela M DeVeaugh-Geiss

    BACKGROUND Discontinuation of buprenorphine as a medication for opioid use disorder (MOUD) necessitates careful tapering to reduce opioid withdrawal and relapse. With a half-life of 43-60 days, buprenorphine extended-release formulation (BUP-XR) may provide gradual taper, facilitating successful treatment discontinuation. OBJECTIVE This study sought to understand experiences with stopping BUP-XR as described on social media. METHODS Reddit records (March 2018 to August 2022) were evaluated for the presence of referents to BUP-XR using parallel criteria based on predefined keywords and subreddit context. The keyword-based search identified records mentioning “Sublocade” (or similar search strings) regardless of subreddit. The subreddit context-based criteria identified records that were created within the r/Sublocade subreddit. Records that included reference to BUP-XR were further evaluated for mentions of treatment cessation using predefined keywords. A 50% randomized sample was then selected for qualitative analysis by a single experienced subject matter expert. Records were manually coded to validate references to BUP-XR and MOUD cessation and were evaluated for additional predefined constructs related to opioid craving and withdrawal, BUP-XR and other MOUD treatment details, and other nonmedical opioid use. Emergent constructs related to cessation-related knowledge, attitudes, behaviors, and experiences were also identified as part of the data coding and annotation process. RESULTS Of 6082 total, 3041 records were coded and analyzed; most (n=2692, 97.4%) referenced BUP-XR, of which, 43.8% (n=1179) referenced cessation of BUP-XR as MOUD. Many individuals shared information about prior use of MOUD, primarily transmucosal buprenorphine (185 records/63 authors), including the use of BUP-XR to taper off buprenorphine. Individuals provided details of their BUP-XR treatment experiences before and following cessation. Only 102 (8.7%) records mentioned opioid withdrawal; 1 record mentioned craving. Withdrawal experiences with BUP-XR were generally described as less intense than other drugs, although at least mild withdrawal was seen as an inevitable part of cessation. Thematic analysis revealed discussions of polypharmacy with transmucosal buprenorphine and the importance of personalized treatment and patient agency. CONCLUSIONS There was nuanced discussion of treatment cessation using BUP-XR on Reddit, with individuals describing detailed courses of treatment and treatment experiences. Few records mentioned opioid withdrawal, and when discussed, withdrawal experiences during cessation of BUP-XR were generally described as less intense than withdrawal experiences with other drugs. These results suggest that social media, such as Reddit, can be leveraged to explore perspectives on treatment and recovery among individuals with opioid use disorder. Overall, this study provides insights into real-world patient experiences with cessation of BUP-XR and is consistent with prior case series; however, more research is needed to understand the course of opioid use disorder following cessation of BUP-XR as well as other MOUD.

  • Top Cited Papers
    Open Access

    An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples

    by Traci C. Green, Ju Nyeong Park, Michael Gilbert, Michelle McKenzie, Eric Struth, Rachel Lucas, William Clarke, Susan G. Sherman


  • Commentary van der Gouwe et al. (2017): Drug-testing services and cryptomarkets come of age.

    by Nabarun Dasgupta, Michael Gilbert

  • Open Access

    Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis

    by Laurie S. Anderson, Heidi G Bell, Michael Gilbert, Julie E Davidson, Christina Winter, Monica J Barratt, Beta Win, Jeffery L Painter, Christopher Menone, Jonathan Sayegh, et al.

    A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.


  • Open Access

    Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone

    by Stevan Geoffrey Severtson, Matthew S. Ellis, Steven P. Kurtz, Andrew Rosenblum, Theodore J. Cicero, Mark W. Parrino, Michael K. Gilbert, Mance E. Buttram, Nabarun Dasgupta, Becki BucherBartelson, et al.


  • Counterfeit Medications and Fentanyl

    by Traci C. Green, Michael Gilbert

    The steep recent increase in overdose deaths and near-deaths nationwide involving fentanyl signals a new chapter in the epidemic of opioid use. Throughout the U


    • 19 June 2015
      • Vol. 64  (23) , 631-635
    Top Cited Papers

    Opioid Overdose Prevention Programs Providing Naloxone to Laypersons — United States, 2014

    by Eliza Wheeler, T. Stephen Jones, Michael K. Gilbert, Peter J. Davidson

    Drug overdose deaths in the United States have more than doubled since 1999. During 2013, 43,982 drug overdose deaths (unintentional, intentional [suicide or homicide], or undetermined intent) were reported. Among these, 16,235 (37%) were associated with prescription opioid analgesics (e.g., oxycodone and hydrocodone) and 8,257 (19%) with heroin. For many years, community-based programs have offered opioid overdose prevention services to laypersons who might witness an overdose, including persons who use drugs, their families and friends, and service providers. Since 1996, an increasing number of programs provide laypersons with training and kits containing the opioid antagonist naloxone hydrochloride (naloxone) to reverse the potentially fatal respiratory depression caused by heroin and other opioids. In July 2014, the Harm Reduction Coalition (HRC), a national advocacy and capacity-building organization, surveyed 140 managers of organizations in the United States known to provide naloxone kits to laypersons. Managers at 136 organizations completed the survey, reporting on the amount of naloxone distributed, overdose reversals by bystanders, and other program data for 644 sites that were providing naloxone kits to laypersons as of June 2014. From 1996 through June 2014, surveyed organizations provided naloxone kits to 152,283 laypersons and received reports of 26,463 overdose reversals. Providing opioid overdose training and naloxone kits to laypersons who might witness an opioid overdose can help reduce opioid overdose mortality.